Seeking Alpha

Baird defends Regeneron (REGN -2.1%) this morning, saying the drug developer's downstream has...

Baird defends Regeneron (REGN -2.1%) this morning, saying the drug developer's downstream has significant potential. The firm cites the beginning of REGN's Phase lll testing of REGN727 next month, plus FDA guidance that cardiovascular outcomes will not be a prerequisite for approval.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs